The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -6.82 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 7.04 — flag raised, worth a closer lookWatch
- Earnings quality 58/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Orchestra BioMed Holdings, Inc. reports it. History and quarterly detail are in the app.
- Partnership revenue$32.9M
- Product revenue$611K
Leadership changes
From Orchestra BioMed Holdings, Inc.'s own filings, the day they're filed.
- Eric Rose · Director · departureeff. 2025-02-03
- Chris Cleary · director · appointmenteff. 2025-01-30
- John Mack · director · appointmenteff. 2024-07-29
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-05-12
- DEF 14A · Annual proxy (pay & governance)2026-04-29
- 10-K · Annual report2026-03-12
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Orchestra BioMed Holdings, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Orchestra BioMed Holdings, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.